novo nordisk glp-1 drugs Nordisk's weight-loss pill wins FDA approval Novo Nordisk launches its Wegovy

The messaging is about affordability and access

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial results reported at AAIC.

This probiotic is designed for adults seeking daily gut health support as part of a wellness routine that includes balanced nutrition and an active lifestyle

This was a game changer